Oral presentations per session
(vers. 26.09.2019)
Abstractbook is online!
| K1 Opening & Keynote Lecture I (plenary) Thursday, 10 October 2019 13:00-13:45 |
||
| Welcome addresses Dagmar Jírová, Vice-President of EUSAAT, CZ-Prague & Horst Spielmann, Chair of the Scientific Committee, DE-Berlin |
||
| Keynote Lecture I Update on human stem cells - scientific, ethical and legal challenges Jürgen Hescheler, DE-Cologne |
||
| K2 Keynote Lecture II (plenary) Friday, 11 October 2019 09:00-09:30 |
||
| Implementing Directive 2010/63/EU - current status and next steps Susanna Louhimies, BE-Brussels |
||
| K3 Keynote Lecture III (plenary) Saturday, 12 October 2019 09:00-09:30 |
||
| Human Artificial Lymph Node Model (HuALN) for biopharmaceutical testing and disease modelling in vitro Christoph Giese, DE-Berlin |
||
| K4 Keynote Lecture IV (plenary) Sunday, 13 October 2019 09:00-09:30 |
||
| Challenging FDA’s requirement for long term studies in dogs for the safety assessment of drugs and pharmaceuticals Mihael H. Polymeropoulos, US-Washington DC |
||
| Björn Ekwall Award Lecture (plenary) Friday, 12 October 2019 17:30-19:00 |
||
| Serum-free media contribute to better reproducibility in in vitro research Jan van der Valk, NL-Utrecht |
||
| 1.1 3D Models & multi-organ-chips (MOC), human-organ-chips (HOC) - I Thursday, 10 October 2019 13:55-15:25 |
||
| 294 | Microphysiological flux balance platform unravels the dynamics of drug induced steatosis Avner Ehrlich, IL-Jerusalem awarded with the YSTA 2019 |
|
| 316 | 3D CNS model of iPSCs derived neuron and glia for high-throughput neurotoxicity screening in Mimetas’ OrganoPlate® Chiwan Chiang, NL-Leiden |
|
| 409 | An in vitro fracture hematoma model as a tool for preclinical drug testing Moritz Pfeiffenberger, DE-Berlin |
|
| 465 | The combination of 3D human cancer tissues and fluid-dynamic drug administration as winning strategy for in vitro drug efficacy testing Silvia Scaglione, IT-Genoa |
|
| 480 | Integrating Organ-on-a-Chip devices on a multimodal, microfluidic platform Eva Zittel, DE-Karlsruhe awarded with the YSTA 2019 |
|
| 1.2 3D Models & multi-organ-chips (MOC), human-organ-chips (HOC) - II Saturday, 12 October 2019 09:40-11:10 |
||
| 487 | Beating organs-on-chip as advanced tools in drug screening: engineered in vitro models of human organs and diseases Roberta Visone, IT-Milan awarded with the YSTA 2019 |
|
| 498 | Development of 3D skin model and 3D skin infection model, as advanced testing tools for the bio-evaluation of novel antimicrobial biomaterials for treating infected wounds Ayesha Idrees, IT-Turin awarded with the YSTA 2019 |
|
| 526 | Biology-Inspired Micro-physiological System Approaches to Solve the Prediction Dilemma of Substance Testing Horst Spielmann, DE-Berlin |
|
| 530 | Brief introduction of user-driven microphysiological system development in Japan Toshiyuki Kanamori, JP-Tsukuba |
|
| 535 | 3D in vitro scaffold based cell model of neuroblastoma for evaluating genotoxic and miRNA-targeted therapeutics Olga Piskareva, IR-Dublin |
|
| 2.1 3R Centers in Europe & international - national and local centers - I Thursday, 10 October 2019 13:55-15:25 |
||
| 331 | Norecopa: working to advance harmonisation and dissemination of best practice in animal research and testing Adrian Smith, NO-Oslo |
|
| 388 | Italian Centro3Rs commitment: 1 year after the opening of the activities Anna Maria Bassi, IT-Genoa |
|
| 398 | At crossroads between regulation, science and industrial application: the EPAA, a public-private initiative for the 3Rs Franz Lamplmair, BE-Brussels |
|
| 434 | A Society for Alternatives to Animal Experiments in India: An Update Mohammad Abdulkader Akbarsha, IN-Tiruchirappalli |
|
| 457 | Austria goes 3R - The RepRefRed Society Birgit Reininger-Gutmann, AT-Graz |
|
| 2.2 3R Centers in Europe & international - national and local centers - II Saturday, 12 October 2019 09:40-11:10 |
||
| 488 | Charité 3R – the 3R Center of Charité Universitätsmedizin Berlin Annemarie Lang, DE-Berlin |
|
| 517 | Slovak National Platform for Three Rs (SNP 3Rs) in Science, Education, Research and Development Helena Kandarova, SK-Bratislava |
|
| 523 | 3Rs Center at the National Institute of Public Health in the Czech Republic Dagmar Jírová, CZ-Prague |
|
| 346 | Animal experiments or humane alternatives: awareness raising campaign in Belarus Tatsiana Hlinkina, BY-Minsk |
|
| 369 | Asian Consortium for Three Rs Hajime Kojima, JP-Tokyo |
|
| 3.1 3Rs in education and academia - I Friday, 11 October 2019 11:40-13:10 |
||
| 383 | Advancing the Three Rs education and training under a European Parliament Pilot Project Susanna Louhimies, BE-Brussels |
|
| 486 | 3Rs education in academia: experiences from the Swiss 3R competence centre Chantra Eskes, CH-Bern |
|
| 328 | Initiatives to promote the Three Rs in education and training Francesca Pistollato, IT-Ispra |
|
| 402 | 3R funding of research activities 2014-2019 in Denmark by the Danish 3R centre Lisbeth Knudsen, DK-Copenhagen |
|
| 3.2 3Rs in education and academia - II Saturday, 12 October 2019 15:30-17:00 |
||
| 340 | Education towards non-animal approaches in basic and applied biomedical research Kathrin Herrmann, US-Baltimore |
|
| 381 | Refinement in education Györgyi Szabó, HU-Budapest |
|
| 513 | Innovations in veterinary education and training and the feasibility of full replacement Nick Jukes, UK-Leicester |
|
| 520 | Time to rethink the 3Rs after 60 years. Time for just 1R: Replacement and non-animal research Candida Nastrucci, IT-Rome |
|
| 4 Advanced safety testing of cosmetics & consumer products and alternatives to animal testing in food safety, nutrition and efficacy Saturday, 12 October 2019 15:30-17:00 |
||
| 337 | Cosmetic perfumes and their potential of endocrine disruption, sensitization and genotoxicity Marketa Dvorakova, CZ-Prague |
|
| 380 | Safety testing of adult novelties using methods in vitro Lada Bělastová, CZ-Prague awarded with the YSTA 2019 |
|
| 451 | Collaboration for non-animal cosmetic safety assessment globally by 2023 Paul Russell, UK-Sharnbrook |
|
| 330 | Gluconeogenic processes in a bovine liver cell line offered short chain fatty acids Anna-Maria Sittel, DE-Leipzig |
|
| 528 | Demonstration of different intestinal absorption mechanisms of lactulose and mannitol by using 3D tissue inserts within fluidic multi-chamber devices Silvia Scaglione, IT-Genoa |
|
paid advertising
|
||
| 5 An integrated interdisciplinary approach to animal-free nanomaterial and chemical safety assessment: Results of the in3 project Thursday, 10 October 2019 16:00-17:30 |
||
| 507 | An introduction to the in3 project Maxime Culot, FR-Lens Paul Jennings, NL-Amsterdam |
|
| 429 | In3 Project: a European initiative to evaluate toxicity of chemicals using iPSCs derived in vitro models: Focus on blood brain barrier models for neurotoxicity assessment Sara Wellens, FR-Lens |
|
| 508 | Study the effect of cyclosporin A on functionality of endothelial cells differentiated from iPS cells as in vitro toxicology model system Zahra Mazidi, AT-Vienna |
|
| 509 | Evaluation of human induced Pluripotent Stem Cell derived podocyte-like cells for toxicity testing Cormac Murphy, NL-Amsterdam |
|
| 493 | In vitro distribution kinetics and neurotoxicity of the cardiac drug amiodarone in the iPSC-derived human 3D model BrainSpheres Carolina Nunes, CH-Lausanne |
|
| 6 Biological barriers Saturday, 12 October 2019 11:40-13:10 |
||
| 360 | Apparent permeability coefficients of ciprofloxacin in human lung epithelial cells appropriately predict bioavailability after inhalation exposure Nico Sonnenschein, DE-Hannover |
|
| 481 | ALT4EI: Assessment of eye irritating potential of 59 chemicals using EpiOcular™ time-to-toxicity (EpiOcular ET-50) neat and dilution protocols Silvia Letasiova, SK-Bratislava |
|
| 432 | The Blood-Saliva Barrier: An optimized in vitro model of the oral epithelium and its relevance for biomarker research Grace Lin, AT-Vienna |
|
| 506 | Modeling of drug toxicity and permeability using the reconstructed 3D model of small intestine Jan Markus, SK-Bratislava |
|
| 496 | Using ex vivo human skin for the assessment of drug transport across the skin barrier with label-free Raman microscopy Nathalie Jung, DE-Frankfurt/Main awarded with the YSTA 2019 |
|
| 7.1 Disease models using HUMAN cells, tissues and organs - I Friday, 11 October 2019 09:40-11:10 |
||
| 304 | Human-based T cell-skin models for graft-versus-host disease Maximiliane Wussmann, DE-Würzburg |
|
| 311 | Neuroprotection via an iNOS-inhibitor in a porcine retina organ culture model Stephanie C Joachim, DE-Bochum |
|
| 355 | Simulating an arthritic joint in vitro by combining multiple tissue components Alexandra Damerau, DE-Berlin |
|
| 379 | Development of an in vitro trabecular human bone model integrated in a perfusion system to simulate glucocorticoid-induced osteoporosis Karoline Diesing, DE-Berlin awarded with the YSTA 2019 |
|
| 459 | Adding DIMENSIONS and a COMPLEMENT-ary view on HIV-1 transmission Doris Wilflingseder, AT-Innsbruck |
|
| 7.2 Disease models using HUMAN cells, tissues and organs - II Sunday, 13 October 2019 09:40-11:10 |
||
| 482 | Cultivation of primary melanoma cells with human platelet lysate or bovine serum show different phenotypic and genotypic characteristics Beate Rinner, AT-Graz |
|
| 484 | In vitro models of human cardiac fibrotic tissue based on bioartificial scaffolds Irene Carmagnola, IT-Turin |
|
| 533 | HepaRG™: an integrated model for studying bile canalicular functions and dysfunctions for studying Cholestasis Toxicity Ashwani Sharma, FR-Saint-Grégoire |
|
| 534 | Sensitive and automated assessment of DNA strand break by AUREA gTOXXs in HepaRGTM Dirk Dressler, DE-Esslingen |
|
| 507 | Transcriptomic, metabolic and toxicological comparison of the human liver derived HepaRG with the human kidney derived RPTEC/TERT1 cells Paul Jennings, NL-Amsterdam |
|
| 8 Ecotoxicology Friday, 11 October 2019 09:40-11:10 |
||
| 335 | Using PLHC-1 topminnow liver cells to characterize and predict the effect of plastic additives in fish Cinta Porte, ES-Barcelona |
|
| 384 | Reliable and representative in silico predictions of freshwater ecotoxicological hazardous concentrations Mélanie Douziech, NL-Nijmegen |
|
| 394 | From initiation to implementation: the RTgill-W1 cell line assay to predict fish acute toxicity of water samples and chemicals (ISO21115) Melanie Fischer, CH-Dübendorf |
|
| 395 | In vivo measurement of 7-methoxycoumarin-O-demethylase activity in zebrafish (Danio rerio) embryos Ann-Kathrin Lörracher, DE-Heidelberg |
|
| 453 | Gene expression upon immune challenge in a fish intestinal in vitro model Stephan Fischer, CH-Wallisellen |
|
| 9.1 Efficacy and safety testing of drugs, medical devices & biopharmaceutics - I Thursday, 10 October 2019 16:00-17:30 |
||
| 442 | Implementing 3Rs by the pharmaceutical industry Kirsty Reid, BE-Brussels |
|
| 411 | Drivers for the pharmaceutical industry to adopt human stem-cell based models Ard Teisman, BE-Beerse |
|
| 458 | Replacement and Reduction examples from Novo Nordisk Thomas Bertelsen, DK-Maaloev |
|
| 454 | From a 3Rs intent to a company's strategy: perspective from the Industry Shahjahan Shaid, BE-Wavre |
|
| 313 | Stakeholder Collaboration to Advance Human-Relevant Nonclinical Methods for Drug Development in the United States Elizabeth Baker, US-Washington DC |
|
| 9.2 Efficacy and safety testing of drugs, medical devices & biopharmaceutics - II Saturday, 12 October 2019 09:40-11:10 |
||
| 466 | Replacement of the potency assay for tick borne encephalitis virus vaccines Dieter Pullirsch, AT-Vienna |
|
| 478 | Development, pre-validation and validation of the EpiDerm in vitro skin irritation protocol for the medical devices extracts Silvia Letasiova, SK-Bratislava |
|
| 502 | Orally inhaled drug products – The strengths and weaknesses of simplified in vitro methods Marius Hittinger, DE-Saarbrücken |
|
| 518 | Development of recombinant antibodies to replace animal sera Maximilian Ruschig, DE-Braunschweig |
|
| 399 | Current status of the implementation of new methods in cardiotoxicity safety testing Christiane Hohensee, DE-Erkrath |
|
| 9.3 Efficacy and safety testing of drugs, medical devices & biopharmaceutics - III Friday, 11 October 2019 15:30-17:00 |
||
| 532 | Vaccine batch to vaccine batch comparison by consistency testing (VAC2VAC) Coenraad Hendriksen, NL-Bilthoven |
|
| 338 | Proteomic analysis of canine leptospira vaccines Thomas Schuenborg, DE-Langen |
|
| 345 | Development of an OECD Test Guideline for Androgen Receptor Transactivation Assays (ARTAs) Anne Milcamps, IT-Ispra |
|
| 529 | Improving Drug Toxicity Assays through the Oxygen-dependent Induction of Metabolic Zonation in Primary Rat Hepatocytes Benedikt Scheidecker, JP-Tokyo |
|
| 366 | 3R-alternatives to skin testing of bovine PPD tuberculins Elisabeth Balks, DE-Langen |
|
| 10 Ethical & legal issues Friday, 11 October 2019 11:40-13:10 |
||
| 412 | Normalizing the unthinkable: The report of the Oxford Centre for Animal Ethics Clair Linzey, UK-Oxford |
|
| 501 | Modernising research and regulatory policies to advance human health Julia Baines, UK-London |
|
| 521 | The impact of closure of specialised mouse research facilities Lindsay Marshall, US-Washington DC |
|
| 389 | Towards veterinary ethics Kerstin Weich, AT-Vienna |
|
| 387 | Why are alternative methods (not) chosen? Presentation of a project on the investigation of value judgments for or against alternatives in animal testing in basic research Ines Pietschmann, DE-Hannover |
|
paid advertising
|
||
| 11 Free communications Sunday, 13 October 2019 11:40-13:10 |
||
| 341 | Are researchers moving away from animal models as a result of poor clinical translation in the field of stroke? A systematic analysis of opinion papers Pandora Pound, UK-Kingsbridge |
|
| 342 | California Cruelty-Free Cosmetics Act establishes first North American law banning the sale of animal tested cosmetics and ingredients Elizabeth Baker, US-Washington DC |
|
| 417 | When the co-culture does not do what it is supposed to do – a step “back” to ex vivo models Sabrina Schnur, DE-Saarbrücken |
|
| 511 | Regulation of Endocrine Disruptors: REACH may change, but will the science evolve? Emma Grange, UK-London |
|
| 421 | Repeating past mistakes: The banality and futility of nowadays cigarette smoke-related animal experimentation Dilyana Filipova, DE-Cologne |
|
| 12 Implementing EU Dir 63/2010 - update Friday, 11 October 2019 09:40-11:10 |
||
| 382 | Project evaluation – importance of a coherent and consistent approach Susanna Louhimies, BE-Brussels |
|
| 452 | A user perspective towards improving the processes of project evaluation Kirsty Reid, BE-Brussels |
|
| 310 | Thematic review of animals used for scientific purposes: a mechanism for advancing replacement Christina Dodkin, UK-London |
|
| 334 | Initiative for better access and digitalisation to EU agencies safety data Francois Busquet, BE-Ixelles |
|
| 362 | Animalstudyregistry.org – a federal database for preregistration of animal research Justyna Chmielewska, DE-Berlin |
|
| 13 In silico models: toxicology & efficacy of drugs, chemicals & cosmetics, new approaches for biomedical research Saturday, 12 October 2019 15:30-17:00 (This session is sponsored by the Lush Prize.) |
||
| 307 | The many cards up ‘computational sleeves’: reshaping in silico tools used in drug discovery to design safer and functional chemicals Jakub Kostal, US-Washington DC |
|
| 352 | Combining in vitro and in silico modelling to simulate cartilage degradation during osteoarthritis Annemarie Lang, DE-Berlin |
|
| 302 | Using big data for developing QSAR models to predict interaction of chemicals with neuronal proteins Yaroslav Chushak, US-Dayton |
|
| 348 | Using the OECD QSAR toolbox as an in silico modelling method for computational aquatic toxicology of endocrine disruptors Dahye Kim, DE-Saarbrücken |
|
| 444 | What can (Q)SAR modelling can tell us about fish toxicity? Pascal Bicherel, FR-L’Isle D’Abeau |
|
| 14 Initiative for implementing serum free culture media Friday, 11 October 2019 15:30-17:00 |
||
| 424 | There is no ethical justification for the use of fetal bovine serum (FBS) Tilo Weber, DE-Neubiberg |
|
| 410 | Using platelet-rich human platelet lysate to substitute fetal calf serum for cultivation of mesenchymal stromal cells Moritz Pfeiffenberger, DE-Berlin |
|
| 542 | A totally defined animal product free cell culture medium for a 3D human tumour out-side the body Stina Oredsson, SE-Lund |
|
| 425 | Björn Ekwall Memorial Award Lecture Serum-free media contribute to better reproducibility in in vitro research Jan van der Valk, NL-Utrecht |
|
| 15 In vitro techniques for CNS toxicity and disease studies Thursday, 10 October 2019 13:55-15:25 |
||
| 323 | An AOP-driven assessment of developmental neurotoxicity induced by chemical mixtures using human iPSC-derived neuronal/glial cultures Francesca Pistollato, IT-Ispra |
|
| 495 | In vitro neurotoxicity testing: functional neuron-specific endpoints Manuela Marcoli, IT-Genoa |
|
| 422 | The relevance of shear stress for in-vitro models of the human blood-brain barrier: a comparative study Anna Gerhartl, AT-Vienna |
|
| 499 | Modelling the human blood-brain-barrier microvasculature and nanocarrier transport on a microfluidic chip Marco Campisi, IT-Turin awarded with the YSTA 2019 |
|
| 16.1 Reduction & refinement - I Friday, 11 October 2019 15:30-17:00 |
||
| 386 | Moving transparency to the next level – Non-technical project summaries under Directive 2010/63/EU Susanna Louhimies, BE-Brussels |
|
| 298 | Does the stress of laboratory life and experimentation on animals adversely affect research data? Jarrod Bailey, UK-London |
|
| 336 | Full implementation of refinement methods in practice through education and training Kathrin Herrmann, US-Baltimore |
|
| 312 | Towards an automated surveillance of well-being in mice using deep learning Katharina Hohlbaum, DE-Berlin awarded with the YSTA 2019 |
|
| 350 | Clicker training for small rodents – cognitive enrichment and beyond Nadine Baumgart, DE-Mainz |
|
| 16.2 Reduction & refinement - II Saturday, 12 October 2019 11:40-13:10 |
||
| 359 | Ethical justification of animal experiments in Germany Christa Thöne-Reineke, DE-Berlin |
|
| 443 | The Animal Protection Quality Certificate. A tool to assess refinement methods in animal experiments Roberto Plasenzotti, AT-Vienna |
|
| 456 | Developing a new simulator of the rat for laboratory animal training courses using 3D printing Giuliano Mario Corte, DE-Berlin |
|
| 531 | Viva3R! Stefanie Schindler, DE-Konstanz |
|
| 414 | Refinement in laboratory animal science education – An inquiry concerning the use of rat and mouse simulators among LAS instructors Melanie Humpenöder, DE-Berlin |
|
| 17 Replacement - advanced technologies Friday, 11 October 2019 11:40-13:10 |
||
| 308 | Transitioning from mammalian animal testing to non-animal testing using the zebrafish (Brachydanio rerio) embryo as a whole organism model for regulatory decision-making in chemical risk assessments Cindy Woodland, CA-Ottawa |
|
| 450 | The importance of data quality and governance in the acceptance of Next Generation risk Assessment (NGRA) approaches Paul Russel, UK-Sharnbrook |
|
| 463 | Bioprinting of 3D organ models for virus and cancer research Jens Kurreck, DE-Berlin |
|
| 492 | Combining fluidic chips and 3D bioprinting - an approach to study tumor-microenvironment and angiogenesis in vitro Michael J. Ausserlechner, AT-Innsbruck |
|
| 440 | The Need for Non-Animal Recombinant Antitoxins Dipti Kapoor, IN-Dehli |
|
| 18 Specific endpoints of toxicity Sunday, 13 October 2019 09:40-11:10 |
||
| 297 | Recent efforts to elucidate the scientific validity of animal-based drug tests by the pharmaceutical industry, pro-testing lobby groups, and animal welfare organisations Jarrod Bailey, UK-London |
|
| 426 | Interpreting irregular LLNA data for evaluation of non-animal methods for skin sensitization David Roberts, UK-Liverpool |
|
| 371 | OECD DRP on in vitro assays in reproductive toxicology Hajime Kojima, JP-Kawasaki |
|
| 525 | Evaluation of in vitro embryotoxicity tests for Chinese herbal medicines Lucia Li, CN-Hangzhou & Horst Spielmann, DE-Berlin |
|
| 19 Stem cell models and technology (hIPS, ES, mES, mIPS…) Thursday, 10 October 2019 16:00-17:30 |
||
| 322 | Human urine as a non-invasive source of kidney progenitor cells amenable for nephrotoxicity studies James Adjaye, DE-Düsseldorf |
|
| 325 | Advancing chemical safety assessments through integration of population-based in vitro models and computational methods Fabian Grimm, US-Annandale |
|
| 536 | Of mice, chicken and human induced pluripotent stem cells: studying midbrain dopaminergic neuron development and survival in the context of Parkinson’s Disease Nilima Prakash, DE-Hamm |
|
| 439 | Generation of hepatic organoids from human induced pluripotent stem cells Hyemin Kim, KR-Daejeon |
|
| 477 | Generation of functional macrophages from human induced pluripotent stem cells SeongYea Jo, KR-Daejeon |
|
| 20 How to account for uncertainties of reference methods & data? Sunday, 13 October 2019 11:40-13:10 |
||
| 357 | Accounting of uncertainties for complex endpoints: What do we want to know? Martin Paparella, AT-Innsbruck |
|
| 449 | Assessment of uncertainties – ECVAM experience from recent in-vitro validation studies Roman Liska, IT-Ispra |
|
| 361 | Fish acute toxicity: Which data do we need and where do we get these from? Thomas Braunbeck, DE-Heidelberg |
|
| 391 | On the uncertainty of toxicological methods: Quantifying the borderline range of prediction models and implications for decision-making Silke Gabbert, NL-Wageningen |
|
| 479 | Animal free development, testing, parameterisation and calibration of human PBPK models for two plasticisers Kevin McNally, UK-Buxton |
|
| 21 Animal experimentation: working towards a paradigm change (inspired by the book with the same title, eds: K. Herrmann and K. Jayne) Sunday, 13 October 2019 11:40-13:10 |
||
| 299 | CRISPR-mediated gene editing: scientific and ethical issues Jarrod Bailey, UK-London |
|
| 385 | Refinement on the way towards Replacement: Are we doing what we can? Kathrin Herrmann, US-Baltimore |
|
| 403 | Animal research for Alzheimer's Disease: failures of science and ethics Francesca Pistollato, IT-Ispra |
|
| 543 | Replacing animal tests to improve safety for humans Jan Turner, UK-Kingsbridge |
|
| 544 | How can the final goal of completely replacing animal procedures successfully be achieved? Carolin Spicher, DE-Munich |
|
| 22.1 'Young Scientists' session - I Saturday, 12 October 2019 11:40-13:10 |
||
| 545 | Session keynote Similarity of a career in the field of 3Rs and a Trans-Alpine Crossing Barbara Birk, DE-Ludwigshafen |
|
| 332 | P. aeruginosa infected co-culture of human cystic fibrosis bronchial epithelial cells as a preclinical test system for anti-infectives Justus Horstmann, DE-Saarbrücken awarded with the YSTA 2019 |
|
| 418 | Development of a test system for the investigation of the pulmonary mucus barrier Nina Grzeschik, DE-Saarbrücken |
|
| 445 | Engineering in vitro Lung Microbiota for Antimicrobial Treatment Daniela Pacheco, IT-Milan awarded with the YSTA 2019 |
|
| 467 | Differentiation of motor neurons for in vitro potency testing of Botulinum Neurotoxins Maren Schenke, DE-Hannover awarded with the YSTA 2019 |
|
| 22.2 'Young Scientists' session - II Sunday, 13 October 2019 09:40-11:10 |
||
| 505 | A novel model for mechanical assessment of biomaterials Constantinos Voniatis, HU-Budapest awarded with the YSTA 2019 |
|
| 504 | A reconstructed human skin model containing macrophages to set up a delayed wound healing model of cutaneous leishmaniasis Priscila Schilrreff, AR-Buenos Aires awarded with the YSTA 2019 |
|
| 433 | An innovative in vitro physiological relevant model as a tool to test therapeutic strategies for glaucoma Stefania Vernazza, IT-Genoa |
|
| 392 | Development of a human pancreatic cell line with optogenetically controllable receptor for high content screening Anna Stierschneider, AT-Krems |
|
| 415 | Design of experimental animal surgical models: Creation of a mouse uterus 3D-model for learning the in-utero electroporation Maximilian Nuber, DE-Mainz |
|
| R1 Round Table I (plenary) International impact of closing research animal facilities in Europe Thursday, 10 October 2019 17:40-19:00 |
||
| R3 Round Table II (plenary) Establishing an International 3Rs Centers Network Saturday, 12 October 2019 17:30-19:00 |
||
| P1 Poster Session I Friday, 11 October 2019 14:00-15:30 |
||
| Survey of the posters with presence of the authors. The titles and authors of this poster session I will be published separately. All posters will be present during all days of the congress. |
||
| P2 Poster Session II Saturday, 12 October 2019 14:00-15:30 |
||
| Survey of the posters with presence of the authors. The titles and authors of this poster session II will be published separately. All posters will be present during all days of the congress. |
||
